221 related articles for article (PubMed ID: 23436932)
1. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Lewis ND; Haxhinasto SA; Anderson SM; Stefanopoulos DE; Fogal SE; Adusumalli P; Desai SN; Patnaude LA; Lukas SM; Ryan KR; Slavin AJ; Brown ML; Modis LK
J Immunol; 2013 Apr; 190(7):3533-40. PubMed ID: 23436932
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
3. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis.
Keul P; Lucke S; von Wnuck Lipinski K; Bode C; Gräler M; Heusch G; Levkau B
Circ Res; 2011 Feb; 108(3):314-23. PubMed ID: 21164103
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
Walter DH; Rochwalsky U; Reinhold J; Seeger F; Aicher A; Urbich C; Spyridopoulos I; Chun J; Brinkmann V; Keul P; Levkau B; Zeiher AM; Dimmeler S; Haendeler J
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):275-82. PubMed ID: 17158356
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
Matloubian M; Lo CG; Cinamon G; Lesneski MJ; Xu Y; Brinkmann V; Allende ML; Proia RL; Cyster JG
Nature; 2004 Jan; 427(6972):355-60. PubMed ID: 14737169
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor.
Whetzel AM; Bolick DT; Srinivasan S; Macdonald TL; Morris MA; Ley K; Hedrick CC
Circ Res; 2006 Sep; 99(7):731-9. PubMed ID: 16960101
[TBL] [Abstract][Full Text] [Related]
10. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
11. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
12. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
[TBL] [Abstract][Full Text] [Related]
13. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
14. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.
Keul P; Tölle M; Lucke S; von Wnuck Lipinski K; Heusch G; Schuchardt M; van der Giet M; Levkau B
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):607-13. PubMed ID: 17158351
[TBL] [Abstract][Full Text] [Related]
15. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Martini S; Krämer S; Loof T; Wang-Rosenke Y; Daig U; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1761-70. PubMed ID: 17356129
[TBL] [Abstract][Full Text] [Related]
16. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
17. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
18. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
Kohno T; Igarashi Y
Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
